Treatment
Deucravacitinib clinical trials
We’re tracking 15 recruiting studies that include Deucravacitinib, each written for real people, not researchers, below.
Recruiting studies
- NCT04772079RecruitingPhase 3
Test drug safety and effectiveness for youth plaque psoriasis
This study checks whether deucravacitinib works well and is safe in children and teens with moderate to severe plaque psoriasis. It also looks at drug levels in the body to help understand how the treatment behaves over time.
Ciudad Autonoma de Buenos Aires, Buenos AiresAges 4–18 - NCT07116967RecruitingPhase 3
Long-term safety of two psoriasis drugs in people with heart risk
This study compares two medications for psoriasis (deucravacitinib and ustekinumab) over a long period. It's designed for people with moderate-to-severe psoriasis who also have certain risk factors for heart disease, like high blood pressure or diabetes.
Birmingham, AlabamaAges 40 years+ - NCT06979453RecruitingPhase 3
A study of deucravacitinib for teens with plaque psoriasis
This trial tests an investigational oral medication called deucravacitinib for teenagers (adolescents) with moderate to severe plaque psoriasis. It aims to see if the drug is safe and works well.
Birmingham, AlabamaAges 12–17 - NCT07508488RecruitingPhase 2
Deucravacitinib for scarring hair loss (Phase 2)
This study tests an oral medication called deucravacitinib for people with scarring hair loss (frontal fibrosing alopecia or central centrifugal cicatricial alopecia). It aims to see if the drug can reduce inflammation and stop or slow hair loss.
New York, New YorkAges 18 years+ - NCT05858645RecruitingPhase 4
Deucravacitinib to correct immune signals in psoriasis
This Phase 4 study tests whether deucravacitinib can improve psoriasis by correcting abnormal immune-cell signals seen in people with moderate-to-severe disease. It may help reduce symptoms and improve control of psoriasis, while researchers also track immune changes.
San Francisco, CaliforniaAges 18–75 - NCT06258668Recruiting
Real-world study of Sotyktu for psoriasis in Korea
This study looks at how safe and effective a pill called Sotyktu is for people with moderate-to-severe plaque psoriasis in real-life medical settings in Korea. If you are 19 or older and are about to start Sotyktu for your psoriasis as your doctor prescribes, this study may be an option for you.
SeoulAges 19 years+ - NCT06382987Recruiting
Comparing deucravacitinib vs apremilast for plaque psoriasis
This study compares two oral medications, deucravacitinib and apremilast, for adults with plaque psoriasis in Japan. It looks at how well each drug works in real-world use.
Minato-ku, TokyoAges 18 years+ - NCT05744466Recruiting
Compare two psoriasis medicines using real-world patient data
This study looks at how well two common plaque psoriasis medicines—deucravacitinib and apremilast—work in everyday care. It may help researchers understand which option performs better in real patients outside of a traditional drug trial.
Waltham, MassachusettsAges 18 years+ - NCT06136403RecruitingPhase 2
Deucravacitinib for genetic skin disorders
This study tests a medication called deucravacitinib for adults with rare genetic skin conditions that cause blisters or severe scaling. The goal is to see if it can reduce symptoms safely.
Nice, CHU de NICEAges 18–99 - NCT06701513Recruiting
Real-world study of deucravacitinib for plaque psoriasis
This study looks at how well deucravacitinib works for adults with moderate to severe plaque psoriasis in everyday medical practice. It helps doctors understand the real-world benefits of this treatment.
AmiensAges 18 years+ - NCT06869551RecruitingPhase 3
Testing a New Drug for Juvenile Psoriatic Arthritis
This study tests an investigational drug called Deucravacitinib to see if it can safely and effectively treat Juvenile Psoriatic Arthritis in children. You may be able to join if standard treatments haven't helped enough.
Lancaster, CaliforniaAges 5–17 - NCT07017699Recruiting
Deucravacitinib safety during pregnancy study
This study looks at how safe the medicine deucravacitinib (used for psoriasis) is during pregnancy. It compares pregnant women who took deucravacitinib to those who did not, to see if there are any effects on the baby.
La Jolla, CaliforniaAges Any age - NCT07256015Recruiting
Deucravacitinib for moderate to severe psoriasis in Italy
This study looks at how well deucravacitinib works for people with moderate to severe plaque psoriasis in real-life settings in Italy. It follows patients who have already started the treatment to see how they are doing.
Verona, VeronaAges 18 years+ - NCT06999941Enrolling by invitation
Study of deucravacitinib for psoriasis with eczema features
This trial tests an oral medication called deucravacitinib for people who have both psoriasis and eczema (or psoriasis that looks like eczema) on their skin. The goal is to see if it can help reduce the severity of their plaques and itch.
Shanghai, Shanghai MunicipalityAges 18–65 - NCT06875960RecruitingPhase 4
Continuing deucravacitinib for people with lupus
This study lets people who have already finished a previous trial of deucravacitinib continue taking the medicine. It is for adults with lupus, including skin-only forms of the disease, to see if long-term treatment remains safe and helpful.
Farmington, ConnecticutAges 18–75
What Deucravacitinib is being studied for
Conditions with recruiting Deucravacitinib studies.
Common questions
- Are there clinical trials studying Deucravacitinib?
- Yes. Clin2 currently lists 15 recruiting studies that include Deucravacitinib, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Deucravacitinib trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Deucravacitinib an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Deucravacitinib or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.